Skip to main content
editorial
. 2008 Jun 28;14(24):3781–3791. doi: 10.3748/wjg.14.3781

Table 2.

Prevalence of pANCA1 in PSC patients and controls2 [% (nantibody positive/ntotal population)]

Authors PSC PSC -IBD PSC+IBD UC -PSC CD-PSC AIH PBC HC MT
Terjung et al[44] 943 814 (142/175) 31 0 IIF
(33/35) (14/45) (0/19) 1:10
Klein et al[54] 87 78 27 0 IIF
(26/30) (18/23) (16/60) (0/20) 1:10
Mulder et al[102] 79 775 825 886 28 5 IIF
(19/24) (10/13) (9/11) (21/24) (7/25) (12/252) 1:32
Lo et al[56] 777 33 0 336 0 0 AP
(23/30) (15/45) (0/32) (1/33) (0/14) (0/50) 1:10
Seibold et al[98] 775 408 88 83 25 336 28 0 IIF
(17/22) (2/5) (15/17) (38/46) (20/80) (5/15) (7/28) (0/30) 1:10
Gur et al[87] 75 75 755 IIF
(15/20) (3/4) (12/16) 1:20
Muratori et al[144] 75 314 2 0 IIF
(18/24) (12/39) (1/51) (0/18) 1:20
Seibold et al[84] 72 50 765 62 4 354 28 0 IIF
(18/25) (2/4) (16/21) (30/48) (2/48) (8/23) (6/21) (0/40) 1:10
Zauli et al[137] 72 IIF
(33/46) -9
Hardarson et al [145] 69 75 675 76 8 506 0 IIF
(20/29) (6/8) (14/21) (16/21) (2/25) (10/20) (0/33) 1:40
Roozendaal et al[99] 67 IIF
(46/69) 1:40
Bansi et al[146] 6610 656 13 0 AP
(57/86) (11/17) (7/55) (0/36) 1:5
5110 656 11 0 IIF
(44/86) (11/17) (6/55) (0/36) 1:5
Bansi et al[101] 65 29 705 45 0 AP
(41/63) (2/7) (39/56) (38/85) (0/36) 1:05
Tervaert et al[88] 62 716 33 0 IIF
(8/13) (5/7) (5/15) (0/24) -9
Roozendal et al[57] 49 7011 15 0 IIF
(27/55) (62/88) (8/53) (0/78) 1:40
Claise et al[53] 44 25 60 37 15 2411 0 0 IIF
(12/27) (3/12) (9/15) (18/49) (11/75) ( 25/105) (0/30) (0/50) 1:20
Vermeulen et al[147] 44 56 15 466 5 IIF
(16/36) (56/100) (15/100) (17/37) (5/105) 1:40
Wilschanski et al[60] 29 IIF
(7/24) 1:20
Pokorny et al[100] 26 29 23 226 0 IIF
(10/39) (5/17) (5/22) (2/9) (0/7) 1:20

PSC: Primary sclerosing cholangitis; IBD: Inflammatory bowel disease; UC: Ulcerative colitis; CD: Crohn’s disease; AIH: Autoimmune hepatitis; PBC: Primary biliary cirrhosis; HC: Healthy controls; MT: Method and titre considered positive (cut-off); IIF: Indirect immunofluorescence; AP: Alkaline phosphatase method.

1

No distinction between classical/atypical;

2

The single largest study of autoantibodies in PSC reported ANCAs among 84% (61/73) of the patients, but this study did not apply IIF, meaning that this figure is the total of patients with any ANCA subspecificity[78];

3

Atypical pANCA (as opposed to classical pANCA or cANCA);

4

autoimmune hepatitis type 1 and 2;

5

Calculated from article values;

6

Autoimmune hepatitis not subclassified (1 or 2);

7

ANCA "type 1 pattern" is interpreted as pANCA, including both IgA/IgM/IgG;

8

Significant difference between PSC +IBD and PSC -IBD (P value not given);

9

Details not given, correspondence, not peer-reviewed;

10

Calculated sum of 4 patient populations from different countries;

11

Autoimmune hepatitis type 1.